The Immune-Mediated Inflammatory Diseases Market is positioned for steady expansion, with a projected CAGR of 7.10% from 2024 to 2031.
Immune-Mediated Inflammatory Diseases covers reshaping how healthcare entities approach this space.
Growth is bolstered by a convergence of factors: rising awareness among end users, continuous product innovation, and the rising emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region set to deliver the strongest growth trajectory through the forecast period, bolstered by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Immune-Mediated Inflammatory Diseases Market Snapshot
Chapter 4. Global Immune-Mediated Inflammatory Diseases Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Immune-Mediated Inflammatory Diseases Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Immune-Mediated Inflammatory Diseases Industry Trends
Chapter 5. Immune-Mediated Inflammatory Diseases Market Segmentation 1: By Indication, Estimates & Trend Analysis
5.1. Market Share by Indication, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Indication:
5.2.1. Asthma, Chronic Obstructive Pulmonary Diseases (COPD)
5.2.2. Inflammatory Bowel Disease (IBD)
5.2.3. Systemic Lupus Erythematosus (SLE)
5.2.4. Rheumatoid Arthritis (RA)
5.2.5. Psoriasis
5.2.6. Others
Chapter 6. Immune-Mediated Inflammatory Diseases Market Segmentation 2: By Treatment Type Area, Estimates & Trend Analysis
6.1. Market Share by Treatment Type Area, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Treatment Types Area:
6.2.1. Traditional Drugs
6.2.2. Biologic Therapies
6.2.3. Novel Therapies
Chapter 7. Immune-Mediated Inflammatory Diseases Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administrations:
7.2.1. Oral
7.2.2. Parenteral
7.2.3. Others
Chapter 8. Immune-Mediated Inflammatory Diseases Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channels:
8.2.1. Hospital Pharmacy
8.2.2. Retail Pharmacy
8.2.3. Others
Chapter 9. Immune-Mediated Inflammatory Diseases Market Segmentation 5: By End User, Estimates & Trend Analysis
9.1. Market Share by End User, 2023 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End Users:
9.2.1. Hospitals
9.2.2. Specialty Clinics
9.2.3. Others
Chapter 10. Immune-Mediated Inflammatory Diseases Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Immune-Mediated Inflammatory Diseases Market, Regional Snapshot 2023 & 2031
10.2. North America
10.2.1. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
10.2.3. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.2.4. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.2.5. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.2.6. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
10.3. Europe
10.3.1. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
10.3.3. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.3.4. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.3.5. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.3.6. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
10.4. Asia Pacific
10.4.1. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024- 2031
10.4.3. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.4.4. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
10.4.5. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.4.6. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts By End User, 2024-2031
10.5. Latin America
10.5.1. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
10.5.3. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.5.4. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.5.5. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.5.6. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
10.6. Middle East & Africa
10.6.1. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
10.6.3. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.6.4. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.6.5. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.6.6. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Pfizer Inc
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Offerings
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Abbvie Inc.
11.2.3. Novartis AG
11.2.4. Amgen Inc.
11.2.5. Boehringer Ingelheim International GmbH.
11.2.6. Merck & Co Inc.
11.2.7. Sun Pharmaceutical Industries Ltd.
11.2.8. Teva Pharmaceuticals Industries Ltd.
11.2.9. AstraZeneca
11.2.10. Ampio Pharmaceuticals Inc.
11.2.11. Lilly
11.2.12. Zydus Group
11.2.13. Akorn, Incorporated
11.2.14. Daiichi Sankyo Company, Limited